These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 25187524)

  • 1. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.
    Vanassche T; Lauw MN; Eikelboom JW; Healey JS; Hart RG; Alings M; Avezum A; Díaz R; Hohnloser SH; Lewis BS; Shestakovska O; Wang J; Connolly SJ
    Eur Heart J; 2015 Feb; 36(5):281-7a. PubMed ID: 25187524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?
    Nieuwlaat R; Dinh T; Olsson SB; Camm AJ; Capucci A; Tieleman RG; Lip GY; Crijns HJ;
    Eur Heart J; 2008 Apr; 29(7):915-22. PubMed ID: 18334476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation.
    Lip GY; Frison L; Grind M;
    J Intern Med; 2008 Jul; 264(1):50-61. PubMed ID: 18266660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
    Diener HC; Eikelboom J; Connolly SJ; Joyner CD; Hart RG; Lip GY; O'Donnell M; Hohnloser SH; Hankey GJ; Shestakovska O; Yusuf S;
    Lancet Neurol; 2012 Mar; 11(3):225-31. PubMed ID: 22305462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
    Hohnloser SH; Pajitnev D; Pogue J; Healey JS; Pfeffer MA; Yusuf S; Connolly SJ;
    J Am Coll Cardiol; 2007 Nov; 50(22):2156-61. PubMed ID: 18036454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
    Lip GY; Connolly S; Yusuf S; Shestakovska O; Flaker G; Hart R; Lanas F; Xavier D; Eikelboom J;
    Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):31-8. PubMed ID: 23390125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial.
    Al-Khatib SM; Thomas L; Wallentin L; Lopes RD; Gersh B; Garcia D; Ezekowitz J; Alings M; Yang H; Alexander JH; Flaker G; Hanna M; Granger CB
    Eur Heart J; 2013 Aug; 34(31):2464-71. PubMed ID: 23594592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
    Eikelboom JW; Connolly SJ; Gao P; Paolasso E; De Caterina R; Husted S; O'Donnell M; Yusuf S; Hart RG
    J Stroke Cerebrovasc Dis; 2012 Aug; 21(6):429-35. PubMed ID: 22818021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial.
    Hohnloser SH; Shestakovska O; Eikelboom J; Franzosi MG; Tan RS; Zhu J; Yusuf S; Connolly SJ
    Eur Heart J; 2013 Sep; 34(35):2752-9. PubMed ID: 23892201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulant and antiplatelet therapy for stroke prevention in atrial fibrillation patients in the clinical practice of a single district hospital in Poland.
    Bednarski J; Cieszewska E; Strzelecki A; Filipiak KJ
    Kardiol Pol; 2013; 71(12):1260-5. PubMed ID: 23990227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.
    Coppens M; Eikelboom JW; Hart RG; Yusuf S; Lip GY; Dorian P; Shestakovska O; Connolly SJ
    Eur Heart J; 2013 Jan; 34(3):170-6. PubMed ID: 23018151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of first-ever stroke in younger patients with atrial fibrillation not recommended for antithrombotic therapy by current guidelines: a population-based study in an East Asian cohort of 22 million people.
    Chang KC; Wang YC; Ko PY; Wu HP; Chen YW; Muo CH; Sung FC; Li TC; Hsu CY
    Mayo Clin Proc; 2014 Nov; 89(11):1487-97. PubMed ID: 25444485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study.
    Xiang W; Zhang J; Liu M; Liu F; Feng X; Wang Y
    Clin Interv Aging; 2015; 10():515-9. PubMed ID: 25767378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial fibrillation and cardioembolic stroke.
    Ferro JM
    Minerva Cardioangiol; 2004 Apr; 52(2):111-24. PubMed ID: 15194993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis.
    Chan PH; Huang D; Yip PS; Hai J; Tse HF; Chan TM; Lip GY; Lo WK; Siu CW
    Europace; 2016 May; 18(5):665-71. PubMed ID: 26504109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Yates SW
    Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry.
    Boriani G; Laroche C; Diemberger I; Fantecchi E; Popescu MI; Rasmussen LH; Dan GA; Kalarus Z; Tavazzi L; Maggioni AP; Lip GY
    Europace; 2016 May; 18(5):648-57. PubMed ID: 26826133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher Risk of Ischemic Events in Secondary Prevention for Patients With Persistent Than Those With Paroxysmal Atrial Fibrillation.
    Koga M; Yoshimura S; Hasegawa Y; Shibuya S; Ito Y; Matsuoka H; Takamatsu K; Nishiyama K; Todo K; Kimura K; Furui E; Terasaki T; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Kameda T; Nagakane Y; Yagita Y; Kario K; Shiozawa M; Sato S; Yamagami H; Arihiro S; Toyoda K;
    Stroke; 2016 Oct; 47(10):2582-8. PubMed ID: 27531346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
    Roldán V; Marín F; Manzano-Fernandez S; Fernández H; Gallego P; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 May; 109(5):956-60. PubMed ID: 23572113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.